{
    "nct_id": "NCT06139107",
    "official_title": "RADIANT Study: Pre-op Radiation With Abemaciclib Andletrozole in Early Stage Breast Cancer",
    "inclusion_criteria": "* Histologically and/or cytologically confirmed diagnosis of invasive (ductal, lobular or mixed histology), Clinically inapparent tumor that is not palpable. (cT1-T2N0)disease. Minimum tumor size of 1.5 cm\n* Expression of ER or progesterone receptors (PR)and negative expression of HER2 per American Society of Clinical Oncology, (ASCO) Common Alerting Protocol (CAP) guidelines\n* Oncotype diagnosis (DX) Breast Recurrence score of less than 25 on core biopsy specimen\n* Post-menopausal status defined:\n* age <60 with amenorrhea for at least 12 months in the absence of prior chemotherapy, tamoxifen, toremifene, or ovarian suppression and estradiol and FSH (follicle stimulating hormone) in postmenopausal range.\n* No clinical suspicion of metastasis disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of follicle stimulating hormone (PFS) â‰¤2\n* Eligible to undergo surgery, either lumpectomy or mastectomy for local treatment of the breast cancer\n* Able to swallow oral medications\n* Adequate organ function for all of the following:\n\nAbsolute Neutrophil (ANC) >1.5 x 10/L Platelets >100 x 10/L Hemoglobin >8 g/dL - May receive erythrocyte transfusions to achieve this level Total Bilirubin <1.5 x Upper Limit of Normal (ULN) Alanine Aminotransferase (ATL) and Aspartate Aminotransferase (AST) <3 x ULN\n\n* HR positive/HER2 -negative breast cancers are allowed as long as no other exclusions exist\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 60 Years",
    "exclusion_criteria": "* History of ipsilateral breast cancer\n* Prior treatment with CDK4/6 inhibitors or aromatase inhibitors\n* History of chest wall or ipsilateral breast radiation\n* Inflammatory breast cancer\n* Needs neoadjuvant chemotherapy\n* Presence of distant metastatic disease\n* Contraindication for surgery\n* Uncontrolled hypertension (systolic blood pressure >190 mm Hg or diastolic blood pressure >100 mm Hg)\n* Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study\n* Life expectancy < 12 weeks\n* History of allergy or hypersensitivity to any of the study drugs\n* Any significant medical condition, laboratory abnormality, or psychiatric illness\n* Serious and/or uncontrolled preexisting medical condition\n* Has had major surgery within 14 days prior to enrollment\n* Has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to enrollment, or is currently enrolled in any other type of medical research\n* Has active systemic bacterial infection\n* Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest",
    "miscellaneous_criteria": ""
}